The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

DelveInsight's“Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted ...

What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show. The BECOME-TSC study evaluated outcomes of Epidiolex (Jazz ...

The St. Louis Business Journal's Innovation in Philanthropy Awards program, now in its sixth year, celebrates local ...

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive ...

Tia Wathra’s daughter Zara, 6, has called Dravet Syndrome, a rare genetic condition that causes cognitive delay, speech delay and unpredictable seizures. Last May, Landyn Ferris, a 16-year-old ...

after the company provided a “long-awaited” update for its Phase 3 study design and timeline of zorevunersen for the treatment of Dravet syndrome. While some investors appeared to be ...

This trial will investigate zorevunersen as a potential treatment for Dravet syndrome, a severe form of epilepsy in children. The study, slated to begin in mid-2025, will assess the efficacy of ...